SAN DIEGO, Jan. 31, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Pacira BioSciences, Inc. (NASDAQ: PCRX) securities between August 2, 2023 and August 8, 2024. Pacira is an American pharmaceutical company committed to developing and providing non-opioid pan management and regenerative health solutions. For more information, submit a form, email attorney Aaron Dumas, Jr., or give us a call at (80 ...

NEW YORK, Jan. 31, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Pacira BioSciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Pacira investors who were adversely affected by alleged securities fraud between August 2, 2023 and August 8, 2024. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/pacira-biosciences-inc-lawsui ...

-- Accomplished Business and Financial Leader, Laura Brege, Appointed Chair -- -- Paul J. Hastings and Andreas Wicki, PhD Retire from Board of Directors -- PARSIPPANY, N.J., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that Laura Brege has been appointed Chair of the Board. Former Chair Paul J. Hastings and Andreas Wicki, PhD. have retired fr ...

NEW YORK, Jan. 30, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=125758&from=4CLASS PERIOD: Augus ...

NEW YORK, Jan. 27, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=124881&from=4 CLASS PERIOD: Augu ...

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Pacira To Contact Him Directly To Discuss Their OptionsIf you purchased or acquired securities in Pacira between August 2, 2023 and August 8, 2024 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310).[You may also click here for additional information]NEW YORK, Jan. 23, 2025 /PRNewswire/ -- Faruqi & Faruqi, LL ...

NEW YORK, Jan. 23, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Pacira BioSciences, Inc. (NASDAQ: PCRX).Shareholders who purchased shares of PCRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/pacira-biosciences-inc-loss-submission-form/?id=124352&from=4CLASS PERIOD: Augus ...

NEW YORK, Jan. 21, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Pacira Biosciences, Inc. ("Pacira" or the "Company") (NASDAQ: PCRX). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.The class action concerns whether Pacira and certain of its offic ...

Shareholders that lost money on Pacira BioSciences, Inc.(PCRX) should contact Levi & Korsinsky about pending Class Action - PCRX ...

-- Brendan Teehan named Chief Commercial Officer and Krys Corbett named Chief Business Officer -- -- Key additions expected to support company's 5x30 path to becoming an innovative biopharmaceutical organization -- PARSIPPANY, N.J., Jan. 21, 2025 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ:PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced two key appointments to its executive leadership team. Brendan Tee ...